Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

809126

registered interest
date	19/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Skin Diseases
house id	1
legislature	25259 pref label House of Commons
question text	What estimate he has made of the number of patients with Erythropoietic Protoporphyria.
tabling member constituency	Newport East
tabling member printed	Jessica Morden
uin	903031
answer	answer is ministerial correction date of answer 19/12/2017 answer text <p>In 2016/17 there were 54 National Health Service admissions in England with a primary diagnosis of Erythropoietic Protoporphyria.</p><p> </p><p>Whilst the numbers of people with a particular rare disease can be very small, 3.5 million people in the United Kingdom have a rare disease. We know, as with the hon. Member’s constituent, that these diseases can have a heart-breaking impact on a person’s health.</p><p> </p><p>That‘s why the UK is committed to building on our position as a world-leader in the diagnosis and treatment of rare diseases.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/12/2017 17:07:30 answering member 4067 label Biography information for Steve Brine
tabling member	1548 label Biography information for Jessica Morden

809129

registered interest
date	19/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Fees and Charges
house id	1
legislature	25259 pref label House of Commons
question text	What recent assessment he has made of trends in the level of fines in relation to dental and prescription charges.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	903036
answer	answer is ministerial correction date of answer 19/12/2017 answer text <p>The NHS Business Services Authority (NHS BSA) issues penalty charge notices (PCNs) for incorrect claims for exemption from National Health Service dental and prescription charges.</p><p>To ensure the integrity of the exemption system the NHS BSA has recently increased the number of checks. In 2016/17, 365,181 PCNs for dental charges and 975,065 for prescription charges were issued. This represents an increase of 90.11% and 90.23%, respectively, on 2015/16. There is a clear process for patients to appeal a PCN if they believe it is unjustified.</p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/12/2017 17:09:22 answering member 4067 label Biography information for Steve Brine
tabling member	4471 label Biography information for Rachael Maskell

808779

registered interest
date	18/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Arthritis: Vitamin D
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with (a) the Royal College of Nursing and (b) other bodies on the potential merits of prescribing vitamin D to patients with arthritis.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	119888
answer	answer is ministerial correction date of answer 22/12/2017 answer text <p>No discussions have taken place.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/12/2017 12:05:16 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

808797

registered interest
date	18/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prescription Drugs: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, for what reasons there was insufficient stock to confer No Cheaper Stock Obtainable (NCSO) status on a 28 pack of 5mg Amlodipine.
tabling member constituency	Fylde
tabling member printed	Mark Menzies
uin	119906
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>In November the market price of amlodipine 5mg tablets was above the reimbursement price listed in the Drug Tariff, therefore the Secretary of State for Health granted a concessionary price. Supplies of amlodipine 5mg remain available from several suppliers.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 21/12/2017 17:45:43 answering member 4067 label Biography information for Steve Brine
tabling member	3998 label Biography information for Mark Menzies

808802

registered interest
date	18/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Spondyloarthritis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to improve the collection of data within the NHS at the (a) national and (b) local level on the incidence, prevalence and outcomes of ankylosing spondylitis and psoriatic arthritis.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	119911
answer	answer is ministerial correction date of answer 22/12/2017 answer text <p>Psoriatic arthritis and ankylosing spondylitis are part of group of musculoskeletal conditions referred to collectively as spondyloarthritis. This term also refers to conditions including: reactive arthritis; enteropathic arthritis; and undifferentiated spondyloarthritis. The National Institute for Health and Care Excellence advises that spondyloarthritis has a reported prevalence in Western Europe of between 0.8% in 1.7%.</p><p> </p><p>Improving Lives - the Work, Health and Disability Green Paper, published on 31 October 2016, set out the Government’s commitment to work with NHS England to identify opportunities for regular collection of data about incidence, prevalence, clinical activity and outcomes of musculoskeletal conditions and services in England. The Government’s Mandate to NHS England reiterated this commitment. On 30 November 2017 the Government published Improving Lives - The Future of Work, Health and Disability in response to the Green Paper. In building on the commitment in the Green Paper to identify opportunities for routine data collection about musculoskeletal incidence, prevalence, clinical activity, and outcomes, the report set out that a data advisory group, led by Arthritis Research UK, has been examining the issue. On 1 December 2017 the advisory group presented its recommendations to NHS England, which is currently considering the appropriate next steps. Improving Lives - The Future of Work, Health and Disability can be found at the following link:</p><p><a href="http://www.gov.uk/government/publications/improving-lives-the-future-of-work-health-and-disability" target="_blank">www.gov.uk/government/publications/improving-lives-the-future-of-work-health-and-disability</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/12/2017 12:59:01 answering member 4067 label Biography information for Steve Brine
tabling member	4488 label Biography information for Martyn Day

808803

registered interest
date	18/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Chronic Illnesses: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of potential savings to the public purse of new medicines for (a) cystic fibrosis and (b) other long-term conditions; and if he will make a statement.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	119912
answer	answer is ministerial correction date of answer 22/12/2017 answer text <p>The Department has made no estimate. Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) provides authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of resources. In developing its guidance, NICE takes into account all the costs and savings associated with the treatment.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/12/2017 11:59:42 answering member 4067 label Biography information for Steve Brine
tabling member	1528 label Biography information for Sir Mike Penning

808806

registered interest
date	18/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to help patients with cystic fibrosis to access the drug Orkambi; and if he will make a statement.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	119915
answer	answer is ministerial correction date of answer 22/12/2017 answer text <p>In July 2016, the National Institute for Health and Care Excellence (NICE), the independent body that develops guidance on drugs and treatments for clinical and cost effectiveness for the National Health Service in England, was unable to recommend Orkambi as a cost effective use of NHS resources.</p><p> </p><p>Since then there has been a constructive dialogue between the company, NHS England and NICE, including discussion hosted through NICE’s confidential ‘Office for Market Access’, although NICE is yet to receive any fresh proposals from Vertex, the company that manufactures Orkambi. Both NHS England and NICE have been consistent in advice to Vertex, that progress can only be made by working through NICE’s appraisal processes and the existing commercial framework.</p><p> </p><p>Any funding decisions in the absence of positive NICE technology appraisal guidance should be made by NHS commissioners based on an assessment of the available evidence and on the basis of an individual patient’s clinical circumstances.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/12/2017 11:52:09 answering member 4067 label Biography information for Steve Brine
tabling member	1528 label Biography information for Sir Mike Penning

808818

registered interest
date	18/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pain: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps the Government is taking to support a UK wide roll-out of ESCAPE-pain to enable self-management and rehabilitation for people with lower-limb chronic joint pain.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	119927
answer	answer is ministerial correction date of answer 22/12/2017 answer text <p>ESCAPE-Pain is a group-based, six week rehabilitation programme which combines exercise and education to help patients manage chronic joint pain using exercise and coping techniques. The programme is endorsed by the National Institute for Health and Care Excellence, and has received Best Practice Awards from the British Society of Rheumatology and Royal Society of Public Health.</p><p> </p><p>The programme, which is running at over 30 sites across England, can be provided in physiotherapy departments, the community and places of work, and lessons can also be accessed via an app that is free to download. Commissioning of self-management and rehabilitation programmes, such as ESCAPE-Pain, is a local matter.</p><p> </p><p>Health is a devolved matter, and decisions about use of the ESCAPE-Pain programme in Wales, Northern Ireland and Scotland would be a matter for the devolved administrations of those countries.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 119928 question first answered 22/12/2017 12:56:10 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

808819

registered interest
date	18/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pain: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps the Government is taking to support the devolved nations access to (a) the ESCAPE-pain programme and (b) other community structured rehabilitation programmes.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	119928
answer	answer is ministerial correction date of answer 22/12/2017 answer text <p>ESCAPE-Pain is a group-based, six week rehabilitation programme which combines exercise and education to help patients manage chronic joint pain using exercise and coping techniques. The programme is endorsed by the National Institute for Health and Care Excellence, and has received Best Practice Awards from the British Society of Rheumatology and Royal Society of Public Health.</p><p> </p><p>The programme, which is running at over 30 sites across England, can be provided in physiotherapy departments, the community and places of work, and lessons can also be accessed via an app that is free to download. Commissioning of self-management and rehabilitation programmes, such as ESCAPE-Pain, is a local matter.</p><p> </p><p>Health is a devolved matter, and decisions about use of the ESCAPE-Pain programme in Wales, Northern Ireland and Scotland would be a matter for the devolved administrations of those countries.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 119927 question first answered 22/12/2017 12:56:10 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

808847

registered interest
date	18/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 17 October 2017 to Question 106474, when the NICE evaluation report through the Commissioning through Evaluation programme on Left Atrial Appendage Occlusion will be published.
tabling member constituency	Knowsley
tabling member printed	Mr George Howarth
uin	119956
answer	answer is ministerial correction date of answer 22/12/2017 answer text <p>NHS England invested in a ‘commissioning through evaluation’ scheme which has provided additional data on the treatment’s cost and clinical effectiveness. NHS England advises that the scheme’s independent Evaluation Report - produced by the National Institute for Health and Care Excellence has been completed and an updated evidence review is being considered at NHS England’s national Clinical Panel in December.</p><p>If the evidence is supportive of a move to a routine commissioning position in the future, we will look to make a decision on a potential change to the national policy position on funding as soon as possible.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 119957 question first answered 22/12/2017 12:01:51 answering member 4067 label Biography information for Steve Brine
tabling member	481 label Biography information for Sir George Howarth